Journal: Pathogens
Article Title: Purinergic Receptor Antagonists Inhibit Hemolysis Induced by Clostridium perfringens Alpha Toxin
doi: 10.3390/pathogens13060454
Figure Lengend Snippet: Effects of different pathway inhibitors on the rCPA-induced hemolysis of human and murine erythrocytes. ( a ) The degree of hemolysis did not change with increasing concentrations of the p38 MAPK inhibitor BIRB 796, implying no involvement in rCPA-induced hemolysis, in contrast to ( b ) the Akt inhibitor API-2, which can significantly inhibit rCPA-induced hemolysis. Regarding the MEK/ERK pathway, ( c ) the ERK inhibitor FR180204 slightly inhibits rCPA-induced hemolysis, ( d ) the MEK1 inhibitor PD334581 and ( e ) MEK1/2 inhibitor SL327 significantly inhibit rCPA-induced hemolysis, in contrast to ( f ) the MEK5/ERK5 inhibitor BIX02189, ( g ) ERK2 inhibitor TCS ERK 11e, and ( h ) ERK5 inhibitor ERK5-IN-1. Values are the mean ± SD ( n = 3). The hemolysis value corresponding to 0 μM of each antagonist and 4.6 μM rCPA was defined as 1. The statistical differences between each concentration of the inhibitor group and normal hemolysis group without inhibitor are indicated by letters a, b, c, and d, respectively, where “a” denotes p < 0.0001, “b” denotes p < 0.001, “c” denotes p < 0.01, “d” denotes p < 0.05, H denotes human red blood cells, and M denotes mouse red blood cells.
Article Snippet: Pyridoxal phosphate-6-azo (benzene-2,4-disulfonic acid) tetrasodium salt hydrate (PPADS), Suramin, MRS2179, Brilliant Blue G(BBG), ATP-2′, 3′-dialdehyde (OxATP), SL327, carbenoxolone disodium salt, mefloquine, apyrase, BIRB 796, DPI (Diphenyleneiodonium), and BIX02189 were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Techniques: Concentration Assay